Document Detail


Differential responses of proliferating versus quiescent cells to adriamycin.
MedLine Citation:
PMID:  10388527     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The relative sensitivity of proliferating and quiescent cells to DNA-damaging agents is a key factor for cancer chemotherapy. Here we undertook a reevaluation of the way that proliferating and quiescent cells differ in their responses and fate to adriamycin-induced damage. Distinct types of assays that measure membrane integrity, metabolic activity, cell size, DNA content, and the ability to proliferate were used to compare growing and quiescent Swiss3T3 fibroblasts after adriamycin treatment. We found that immediately after adriamycin treatment of growing cells, p53 and p21(Cip1/Waf1) were induced but the cells remained viable. In contrast, less p53 and p21(Cip1/Waf1) were induced in quiescent cells after adriamycin treatment, but the cells were more prone to immediate cell death, possibly involving apoptosis. Adriamycin induced a G2/M cell cycle arrest in growing cells and a concomitant increase in cell size. In contrast, adriamycin induced an increase in sub-G1 DNA content in quiescent cells and a decrease in cell size. In contrast to the short-term responses, adriamycin-treated quiescent cells have a better long-term survival and proliferation potential than adriamycin-treated growing cells in colony formation assays. These data suggest that proliferating and resting cells are remarkably different in their short-term and long-term responses to adriamycin.
Authors:
W Y Siu; T Arooz; R Y Poon
Related Documents :
16969127 - The limitless role of p53 in cell cycle machinery: good news or bad news?
10392637 - Enhanced epithelial cell turnover associated with p53 accumulation and high p21waf1/cip...
10781687 - Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line.
18596907 - A role for polyploidy in the tumorigenicity of pim-1-expressing human prostate and mamm...
219297 - A serological assay for the detection of cell surface receptors of nerve growth factor.
21340847 - Quantification of cell motility : gold colloidal phagokinetic track assay and wound hea...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Experimental cell research     Volume:  250     ISSN:  0014-4827     ISO Abbreviation:  Exp. Cell Res.     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-08-25     Completed Date:  1999-08-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0373226     Medline TA:  Exp Cell Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  131-41     Citation Subset:  IM    
Copyright Information:
Copyright 1999 Academic Press.
Affiliation:
Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3T3 Cells
Animals
Antibiotics, Antineoplastic / pharmacology*
Cell Cycle
Cell Division / drug effects
Cell Survival / drug effects
Cyclin-Dependent Kinase Inhibitor p21
Cyclins / biosynthesis
Doxorubicin / pharmacology*
Mice
Rats
Trypan Blue
Tumor Suppressor Protein p53 / biosynthesis
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Cdkn1a protein, mouse; 0/Cdkn1a protein, rat; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Cyclins; 0/Tumor Suppressor Protein p53; 23214-92-8/Doxorubicin; 72-57-1/Trypan Blue

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chroni...
Next Document:  Characterization of NF-L and betaIISigma1-spectrin interaction in live cells.